

Substitute for form 1449/PTO  
(Revised 04/2003)

JUL 22 2004

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	007157/279516
-------	---	----	---	------------------------	---------------

**Complete if Known**

Application Number	10/813,507
Filing Date	3/30/04
First Named Inventor	Lollar
Group Art Unit	1635
Examiner Name	To be Assigned Terra C. Gibbs

Sheet	1	of	2	Attorney Docket Number	007157/279516
-------	---	----	---	------------------------	---------------

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
/TCG/	1	US-5,364,771	11-15-1994	Lollar <i>et al.</i>	Whole Document
	2	US-5,583,209	12-10-1996	Lollar <i>et al.</i>	Whole Document
	3	US-5,663,060	09-02-1997	Lollar <i>et al.</i>	Whole Document
	4	US-5,744,446	04-28-1998	Lollar <i>et al.</i>	Whole Document
	5	US-5,859,204	01-12-1999	Lollar	Whole Document
	6	US-5,888,974	03-30-1997	Lollar <i>et al.</i>	Whole Document
	7	US-6,180,371	01-30-2001	Lollar	Whole Document
↓	8	US-6,376,463	04-23-2002	Lollar	Whole Document
/TCG/	9	US-6,458,563	10-1-2002	Lollar	Whole Document

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
-------------------	----------	--	--------------------------------	--	---	--

**OTHER DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
/TCG/	10	BARROW, R.T., <i>et al.</i> , "Antigenicity of Putative Phospholipid Membrane-Binding Residues in Factor VIII," <i>Blood</i> , 2001, pp. 169-174, Vol. 97 No. 1.	
/TCG/	11	BARROW, R.T., <i>et al.</i> , "Reduction of the Antigenicity of Factor VIII Toward Complex Inhibitory Antibody Plasmas Using Multiply-Substituted Hybrid Human/Porcine Factor VIII Molecules," <i>Blood</i> , 2000, pp. 564-568, Vol. 95, No. 2.	
/TCG/	12	BOWIE, E.J., and C.A. Owen, "The Clinical and Laboratory Diagnosis of Hemorrhagic Disorders," <i>Grune &amp; Stratton, Inc.</i> , Orlando, 1984, pp. 43-72.	
/TCG/	13	CHANG, J., <i>et al.</i> , "Changing Residue 338 in Human Factor IX from Arginine to Alanine Causes an Increase in Catalytic Activity," <i>The Journal of Biological Chemistry</i> , 1998, pp. 12089-12094, Vol. 273, No. 20, The American Society for Biochemistry and Molecular Biology, Inc., USA.	
Examiner Signature		Date Considered /Terra Cotta Gibbs/	03/20/2008

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449/PTO  
(Revised 04/2003)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

				<b>Complete if Known</b>	
				Application Number	10/813,507
				Filing Date	3/30/04
				First Named Inventor	Lollar
				Group Art Unit	164 ➤ 1635
				Examiner Name	To be Assigned Terra C. Gibbs
Sheet	1	of	2	Attorney Docket Number	007157/279516
/TCG/		14	DOERING, C.B., <i>et al.</i> , "High Level Expression of Recombinant Porcine Coagulation Factor VIII," <i>The Journal of Biological Chemistry</i> , 2002, pp. 38345-38349, Vol. 277, No. 41, The American Society for Biochemistry and Molecular Biology, Inc., USA.		
		15	FUNK, W.D., <i>et al.</i> , "Expression of the Amino-Terminal Half-Molecule of Human Serum Transferrin in Cultured Cells and Characterization of Recombinant Protein," <i>Biochemistry</i> , 1990, pp. 1654-1660, Vol. 29, No. 6.		
		16	HEALEY, J.F., <i>et al.</i> , "Residues Glu2181-Val2243 Contain a Major Determinant of the Inhibitory Epitope in the C2 Domain of Human Factor VIII," <i>Blood</i> , 1998, pp. 3701-3709, Vol. 92, No. 10.		
		17	HEALEY, J.F., <i>et al.</i> , "Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII," <i>The Journal of Biological Chemistry</i> , 1995, pp. 14505-14509, Vol. 270, No. 24.		
		18	KAUFMAN, R.J., <i>et al.</i> , "Biosynthesis, Assembly and Secretion of Coagulation Factor VIII," <i>Blood Coagulation and Fibrinolysis</i> , 1997, pp. S3-S14, Vol. 8 (Suppl 2), Rapid science Publishers.		
		19	LIND, P., <i>et al.</i> , "Novel Forms of B-Domain-Deleted Recombinant Factor VIII Molecules Construction and Biochemical Characterization," <i>Eur. J. Biochem.</i> , 1995, pp. 19-27, Vol. 232.		
		20	LOLLAR, P., "Mapping factor VIII Inhibitor Epitopes Using Hybrid Human/Porcine Factor VIII Molecules," <i>Haematologica</i> , 2000, pp. 26-30, Vol. 85 (Suppl. to n. 10).		
		21	LUBIN, I.M., <i>et al.</i> , "Elimination of a Major Inhibitor Epitope in Factor VIII," <i>The Journal of Biological Chemistry</i> , 1994, pp. 8639-8641, Vol. 269, No. 12, The American Society for Biochemistry and Molecular Biology, Inc., USA.		
		22	PRESCOTT, R., <i>et al.</i> , "The Inhibitor Antibody Response is More Complex in Hemophilia A Patients Than in Most Nonhemophiliacs with Factor VIII Autoantibodies," <i>Blood</i> , 1997, pp. 3663-3671, Vol. 89, No. 10.		
V		23	VEHAR, G.A., <i>et al.</i> , "Structure of Human Factor VIII," <i>Nature</i> , 1984, pp. 337-342, Vol. 312.		
/TCG/		24	ZHONG, D., <i>et al.</i> , "Some Human Inhibitor Antibodies Interfere with Factor VIII Binding to Factor IX," 1998, pp. 136-142, Vol. 92, No. 1.		
Examiner Signature	/Terra Cotta Gibbs/			Date Considered	03/20/2008

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.